Basic Information
Risperidone Mevon 2mg Tablets
TABLET, FILM COATED
Regulatory Information
SIN13522P
August 15, 2008
Prescription Only
Therapeutic
ORAL
August 10, 2023
June 3, 2025
XN05AX08
Company Information
Active Ingredients
Strength: 2mg
Detailed Information
Contraindications
**CONTRAINDICATIONS** Risperidone is contraindicated in patients with a known hypersensitivity to the product.
Indication Information
**INDICATIONS** Risperidone is indicated for the treatment of a broad range of patients with schizophrenia, including first episode psychoses, acute schizophrenic exacerbations, chronic schizophrenia, and other psychotic conditions, in which positive symptoms (such as hallucinations, delusions, thought disturbances, hostility, suspiciousness), and/or negative symptoms (such as blunted affect, emotional and social withdrawal, poverty of speech) are prominent. Risperidone alleviates affective symptoms (such as depression, guilt feelings, anxiety) associated with schizophrenia. Risperidone is also effective in maintaining the clinical improvement during continuation therapy in patients who have shown an initial treatment response. Risperidone is indicated for the short-term treatment of persistent aggression in patients with moderate to severe dementia of the Alzheimer’s type unresponsive to non-pharmacological approaches and when there is a risk of harm to self or others. Risperidone is indicated for the treatment of behavioural disorders associated with autism (eg irritability, social withdrawal, stereotypic behaviour, hyperactivity and inappropriate speech) in children and adolescents. Risperidone is also indicated for bipolar mania. Adjunctive therapy: Risperidone is indicated as adjunctive therapy to mood stabilizers in the treatment of manic episodes associated with bipolar disorders. These episodes are characterized by symptoms such as elevated, expansive or irritable mood, inflated self-esteem, decreased need for sleep, pressured speech, racing thoughts, distractibility, or poor judgment, including disruptive or aggressive behaviors. Monotherapy: Risperidone is indicated in the treatment of acute manic episodes associated with bipolar 1 disorder. The effectiveness of Risperidone for more than 12 weeks of treatment of an acute episode, and for the prevention of new manic episodes has not been established. Risperidone is indicated in the treatment of conduct and other disruptive behavior disorders in children (over 5 years), adolescents and adults with subaverage intellectual functioning or mental retardation in whom destructive behaviors (e.g. aggression, impulsivity and self-injurious behaviors) are prominent. As with all symptomatic treatments, the continued use of Risperidone must be evaluated and justified on an ongoing basis.